[Treatment of the polycystic ovary syndrome (author's transl)]. 1981

J Buvat, and M Buvat-Herbaut

A better understanding of the polycystic ovary syndrome (POS) may help to institute a more rational treatment adapted to each individual case. Seven therapeutic methods have been used until now, progestogens constituting the minimal treatment. Combined oestrogen and progestogen therapy remains basic as long as pregnancy is not desired and should include an anti-androgenic progestogen if hirsutism is to be reduced. Anti-oestrogens have dramatically improved the treatment of sterility and could be used against POS with certain precautions. Parenteral gonadotropins of the HMG variety are usually contra-indicated. Ovarian wedge resection has few indications in view of the risk of post-operative adhesions. Dexamethasone has restored ovulation in some cases. Bromocriptine has recently given promising results. The indications of these various treatments depend on the results to be achieved: endometrial carcinoma must always be prevented, regular menstrual cycles should often be re-established, hirsutism must be avoided or reduced, and fertility should be restored or at least preserved for the future by breaking the hormonal vicious circle. The high incidence of obesity and a possible desire for contraception should also be taken into account.

UI MeSH Term Description Entries
D011085 Polycystic Ovary Syndrome A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading. Stein-Leventhal Syndrome,Polycystic Ovarian Syndrome,Polycystic Ovary Syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary Syndrome,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,Sclerocystic Ovary,Stein Leventhal Syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006062 Gonadotropins Hormones that stimulate gonadal functions such as GAMETOGENESIS and sex steroid hormone production in the OVARY and the TESTIS. Major gonadotropins are glycoproteins produced primarily by the adenohypophysis (GONADOTROPINS, PITUITARY) and the placenta (CHORIONIC GONADOTROPIN). In some species, pituitary PROLACTIN and PLACENTAL LACTOGEN exert some luteotropic activities. Gonadotropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000726 Androgen Antagonists Compounds which inhibit or antagonize the biosynthesis or actions of androgens. Androgen Antagonist,Antiandrogen,Antiandrogens,Anti-Androgen Effect,Anti-Androgen Effects,Antiandrogen Effect,Antiandrogen Effects,Antagonist, Androgen,Antagonists, Androgen,Anti Androgen Effect,Anti Androgen Effects,Effect, Anti-Androgen,Effect, Antiandrogen,Effects, Anti-Androgen,Effects, Antiandrogen
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen

Related Publications

J Buvat, and M Buvat-Herbaut
February 1978, La Nouvelle presse medicale,
J Buvat, and M Buvat-Herbaut
July 1998, Health news (Waltham, Mass.),
J Buvat, and M Buvat-Herbaut
February 2004, Minerva ginecologica,
J Buvat, and M Buvat-Herbaut
June 1980, Nihon Sanka Fujinka Gakkai zasshi,
J Buvat, and M Buvat-Herbaut
July 1974, Horumon to rinsho. Clinical endocrinology,
J Buvat, and M Buvat-Herbaut
October 1964, Journal of the American Medical Women's Association,
J Buvat, and M Buvat-Herbaut
January 1983, La Clinica terapeutica,
J Buvat, and M Buvat-Herbaut
June 1999, Endocrinology and metabolism clinics of North America,
J Buvat, and M Buvat-Herbaut
August 2003, Seminars in reproductive medicine,
J Buvat, and M Buvat-Herbaut
May 1999, Ginekologia polska,
Copied contents to your clipboard!